Overview

Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The experiment is divided into two parts: Part 1 and Part 2.Part 1 was the initial treatment patient and Part 2 was the treated patient.
Phase:
Phase 2
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.
Treatments:
Antiviral Agents
Entecavir
Ritonavir